
Hudson Therapeutics and Shaperon Deepen Licensing Discussions for NuGel Following Bio Europe Spring 2025
Due Diligence underway as clinical data of NuGel, Atopic Dermatitis Treatment is shared for in-depth licensing out discussion DURHAM, NC, UNITED STATES, March 28, 2025 /EINPresswire.com/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, today …